These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28300554)

  • 1. Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy.
    Chen KH; Chou YC; Hsiao CY; Chien Y; Wang KL; Lai YH; Chang YL; Niu DM; Yu WC
    Biochem Biophys Res Commun; 2017 Apr; 486(2):293-299. PubMed ID: 28300554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Proinflammatory Prognostic Biomarkers for Fabry Cardiomyopathy With Enzyme Replacement Therapy.
    Chen KH; Chien Y; Wang KL; Leu HB; Hsiao CY; Lai YH; Wang CY; Chang YL; Lin SJ; Niu DM; Chiou SH; Yu WC
    Can J Cardiol; 2016 Oct; 32(10):1221.e1-1221.e9. PubMed ID: 26919792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
    van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
    Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.
    Arends M; Wijburg FA; Wanner C; Vaz FM; van Kuilenburg ABP; Hughes DA; Biegstraaten M; Mehta A; Hollak CEM; Langeveld M
    Mol Genet Metab; 2017 Jun; 121(2):157-161. PubMed ID: 28495078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
    Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
    Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
    Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
    Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
    PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.
    Smid BE; Rombach SM; Aerts JM; Kuiper S; Mirzaian M; Overkleeft HS; Poorthuis BJ; Hollak CE; Groener JE; Linthorst GE
    Orphanet J Rare Dis; 2011 Oct; 6():69. PubMed ID: 22041095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic progression to clinical phenotype in classic Fabry disease.
    Spada M; Kasper D; Pagliardini V; Biamino E; Giachero S; Porta F
    Ital J Pediatr; 2017 Jan; 43(1):1. PubMed ID: 28049500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.
    Mauhin W; Lidove O; Amelin D; Lamari F; Caillaud C; Mingozzi F; Dzangué-Tchoupou G; Arouche-Delaperche L; Douillard C; Dussol B; Leguy-Seguin V; D'Halluin P; Noel E; Zenone T; Matignon M; Maillot F; Ly KH; Besson G; Willems M; Labombarda F; Masseau A; Lavigne C; Froissart R; Lacombe D; Ziza JM; Hachulla E; Benveniste O
    Orphanet J Rare Dis; 2018 Jul; 13(1):127. PubMed ID: 30064518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.
    Rombach SM; Dekker N; Bouwman MG; Linthorst GE; Zwinderman AH; Wijburg FA; Kuiper S; Vd Bergh Weerman MA; Groener JE; Poorthuis BJ; Hollak CE; Aerts JM
    Biochim Biophys Acta; 2010 Sep; 1802(9):741-8. PubMed ID: 20471476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
    Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
    Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?
    Ozer H; Baloglu I; Topkac A; Ozturk Y; Yonet F; Daglı F; Kilinc İ; Turkmen K
    Nefrologia (Engl Ed); 2024; 44(2):217-223. PubMed ID: 37179210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.
    Sakuraba H; Togawa T; Tsukimura T; Kato H
    Clin Exp Nephrol; 2018 Aug; 22(4):843-849. PubMed ID: 29288396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine.
    Rombach SM; van den Bogaard B; de Groot E; Groener JE; Poorthuis BJ; Linthorst GE; van den Born BJ; Hollak CE; Aerts JM
    Hypertension; 2012 Oct; 60(4):998-1005. PubMed ID: 22868390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry.
    Krüger R; Tholey A; Jakoby T; Vogelsberger R; Mönnikes R; Rossmann H; Beck M; Lackner KJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():128-35. PubMed ID: 22138589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.
    Nowak A; Mechtler TP; Desnick RJ; Kasper DC
    Mol Genet Metab; 2017; 120(1-2):57-61. PubMed ID: 27773586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.